CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-small cell lung cancer.
  
  LEARNING OBJECTIVES

  • Evaluate the various oncogenic alterations identifiable in the epidermal growth factor receptor (EGFR) tyrosine kinase domain and determine how these may predict potential response to currently available EGFR-directed therapies.
  • Acknowledge the FDA approval of adjuvant EGFR tyrosine kinase inhibitor (TKI) therapy for localized EGFR mutation-positive non-small cell lung cancer (NSCLC), and identify patients for whom treatment with this novel approach would be warranted.
  • Evaluate published and emerging clinical trial findings supporting the use of EGFR TKI therapy alone and in combination with other systemic treatments as first-line therapy for patients with metastatic NSCLC and an actionable EGFR mutation and consider the effect of this information on current and future clinical practice.
  • Develop an optimal approach to the management of EGFR mutation-positive NSCLC and CNS metastases, considering the implications of symptomatology, number of lesions and other relevant factors.
  • Describe mechanisms of tumor resistance to EGFR TKIs and discern how available and investigational therapies can be optimally employed in the protocol and nonresearch care of patients with progressive EGFR mutation-positive disease.
  • Evaluate the mechanism of action and published research data with FDA approved novel treatment approaches for patients with NSCLC and an EGFR exon 20 insertion mutation, and consider how these therapies fit into current clinical management algorithms.
  • Recall the biological rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches for patients with EGFR mutation-positive NSCLC.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 2.75 (audio) and 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:
  
  Audio Program: ResearchToPractice.com/EGFRNSCLCThinkTank2024 and evaluation ResearchToPractice.com/EGFRNSCLCThinkTank2024/CME.
  
  Video Program: ResearchToPractice.com/EGFRNSCLCThinkTank2024/Video and evaluation ResearchToPractice.com/EGFRNSCLCThinkTank2024/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Pasi A Jänne, MD, PhD
  Senior Vice President for Translational Medicine
  Lowe Center for Thoracic Oncology
  Professor of Medicine
  Harvard Medical School
  David M Livingston, MD, Chair
  Director, Robert and Renée Belfer Center for Applied Cancer Science
  Director, Chen-Huang Center for EGFR-Mutant Lung Cancers
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, Accutar Biotechnology Inc, Allorion Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Inc, Dizal Pharma, Duality Biologics, Eisai Inc, Frontier Medicines, Genentech, a member of the Roche Group, Hongyun Biotechnology, Lilly, Merus, Mirati Therapeutics Inc, Monte Rosa Therapeutics, Novartis, Nuvalent, Pfizer Inc, Roivant, Sanofi, Scorpion Therapeutics, SFJ Pharmaceuticals, Syndax Pharmaceuticals (myself; compensated), Takeda Pharmaceuticals USA Inc, Transcenta, Voronoi; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Lilly, Puma Biotechnology Inc, Revolution Medicines, Takeda Pharmaceuticals USA Inc.
  
  Tom John, MD
  Associate Professor
  Medical Oncologist
  Peter MacCallum Cancer Centre
  Melbourne, Australia
  
  No relevant conflicts of interest to disclose.
  
  Zofia Piotrowska, MD, MHS
  Assistant Professor of Medicine
  Harvard Medical School
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Janssen Biotech Inc, Lilly, Merck, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo Inc, Janssen Biotech Inc, Novartis, Phanes Therapeutics Inc, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group; Travel Support: Janssen Biotech Inc; Nonrelevant Financial Relationship (Spouse): Employed by Blue Cross Blue Shield of Massachusetts.
  
  Alexander I Spira, MD, PhD
  CEO and Clinical Director, NEXT Virginia
  Director, Virginia Cancer Specialists Research Program
  Fairfax, Virginia
  
  Advisory Committees: Amgen Inc, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Gritstone bio, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, ADC Therapeutics, AI Therapeutics, Alkermes, Amgen Inc, ArriVent Biopharma, Astellas, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, BluPrint Oncology, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo Inc, Gritstone bio, Ignyta Inc, Incyte Corporation, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MacroGenics Inc, Medikine, Mersana Therapeutics Inc, Nalo Therapeutics, Novartis, Plexxikon Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Revolution Medicines, Roche Laboratories Inc, Rubius Therapeutics, Scorpion Therapeutics, Synthekine, Takeda Pharmaceuticals USA Inc; Honoraria: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, CytomX Therapeutics, Janssen Biotech Inc, Merck, Novartis, Prelude Therapeutics, Takeda Pharmaceuticals USA Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Black Diamond Therapeutics Inc and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Release date: September 2024
  Expiration date: September 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.